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Imiquimod Enhances IFN-c Production and Effector
Function of T Cells Infiltrating Human Squamous Cell
Carcinomas of the Skin
Susan J. Huang1, Dirkjan Hijnen2, George F. Murphy3, Thomas S. Kupper1, Adam W. Calarese1,
Ilse G. Mollet4, Carl F. Schanbacher1, Danielle M. Miller1, Chrysalyne D. Schmults1 and Rachael A. Clark1
Squamous cell carcinomas (SCCs) are sun-induced skin cancers that are particularly numerous and aggressive
in patients taking T-cell immunosuppressant medications. Imiquimod is a topical immune response modifier
and Toll-like receptor 7 (TLR7) agonist that induces the immunological destruction of SCC and other skin
cancers. TLR7 activation by imiquimod has pleiotropic effects on innate immune cells, but its effects on T cells
remain largely uncharacterized. Because tumor destruction and formation of immunological memory are
ultimately T-cell-mediated effects, we studied the effects of imiquimod therapy on effector T cells infiltrating
human SCC. SCC treated with imiquimod before excision contained dense T-cell infiltrates associated with
tumor cell apoptosis and histological evidence of tumor regression. Effector T cells from treated SCC produced
more IFN-g, granzyme, and perforin and less IL-10 and transforming growth factor-b (TGF-b) than T cells from
untreated tumors. Treatment of normal human skin with imiquimod induced activation of resident T cells and
reduced IL-10 production but had no effect on IFN-g, perforin, or granzyme, suggesting that these latter effects
arise from the recruitment of distinct populations of T cells into tumors. Thus, imiquimod stimulates tumor
destruction by recruiting cutaneous effector T cells from blood and by inhibiting tonic anti-inflammatory signals
within the tumor.
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INTRODUCTION
More than 100,000 squamous cell carcinomas (SCC) of the
skin are diagnosed in the United States each year (Diepgen
and Mahler, 2002). The treatment of non-melanoma skin
cancer, of which SCC is the second most frequent type,
accounts for 4.5% of all Medicare cancer costs (Housman
et al., 2003). Actinic keratoses (AKs), the premalignant
precursors to SCC, are the third most common reason for
consulting a dermatologist (Feldman et al., 1998). More than
5.2 million physician visits are made annually for the
treatment of AKs, at a cost of over $900 million (Warino
et al., 2006).
Recipients of solid organ transplants on immunosuppres-
sive medications have a 65- to 250-fold increased risk of SCC
(Berg and Otley, 2002). SCCs in these patients are aggressive;
nearly 10% of these tumors metastasize and the majority of
patients die as a result (Berg and Otley, 2002; Euvrard et al.,
2003). The development of SCC in transplant recipients is
linked to the use of medications that suppress T-cell function
(Euvrard et al., 2003).
We have found that blood vessels in human SCC lack
E-selectin, allowing the tumor to exclude skin-homing
effector T cells, while at the same time recruiting regulatory
T cells (Treg cells), a cell type that can suppress immune
responses (Sakaguchi et al., 1995; Clark et al., 2008). We
found that the TLR7 agonist, imiquimod, acted indirectly to
address both of these mechanisms of immune evasion,
inducing E-selectin on blood vessels and allowing the influx
of skin homing T cells, as well as reducing the number and
activity of tumor Treg cells (Clark et al., 2008).
Effector T cells are critical for both the destruction of SCC
and the establishment of long-term, protective immunologi-
cal memory. Despite their importance, comprehensive
studies of the phenotype and function of these cells in SCC
are lacking. Similarly, imiquimod has been shown to induce
IFN-g production in vitro from mouse and human T cells, but
the effect of this medication on tumor-resident T cells has not
been studied thoroughly (Wagner et al., 1999). We present
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here our findings that imiquimod therapy significantly
enhances the number and effector function of T cells
infiltrating human SCC of the skin.
RESULTS
Imiquimod-treated SCCs are infiltrated by CD8þ T cells that
are associated with tumor cell apoptosis and histological
evidence of tumor regression
We have reported earlier that untreated SCCs are infiltrated
by equal numbers of CD4þ and CD8þ T cells, whereas
tumors treated with imiquimod before excision contain
490% CD8þ cytotoxic T cells (Clark et al., 2008). To study
the distribution and characteristics of these cells, we co-
stained cryosections of imiquimod-treated SCC for CD8þ
and for markers of tumor cell proliferation and apoptosis
(Figure 1). We found that imiquimod-treated SCC had three
clear histological zones. First, an area of residual tumor cells,
many of which were proliferating, was evident superficially
(Figure 1a and b). A dense, band-like infiltrate of CD8þ
T cells was present beneath the tumor and a zone of fibrotic
regression was present beneath the T-cell infiltrates. The zone
of fibrotic regression was always present at the base of the
specimen and its width varied with the amount of residual
tumor; tumors that had almost fully regressed had the thickest
zones of fibrosis and those in the earlier stages of destruction
had fibrosis limited to the deeper portions of the dermis. In all
specimens, fibrosis was uniform across the base, suggesting
that fibrosis was not the result of scarring from a prior biopsy
procedure. Dense infiltrates of CD8þ T cells surrounded
nests of residual tumor, and their presence was associated
with tumor cell apoptosis as evidenced by TUNEL staining
(Figure 1d). Untreated SCCs were infiltrated by fewer CD8þ
T cells and they lacked both fibrotic regression and tumor cell
apoptosis (data not shown).
Production of IFN-c, perforin, and granzyme is markedly
enhanced in T cells from imiquimod-treated SCC
We isolated the T cells from untreated and imiquimod-treated
SCC and examined the production of cytokines and proteins
associated with cytotoxic activity. Approximately 50% of
T cells infiltrating untreated SCC are FOXP3þ Treg cells
(Clark et al., 2008). For these studies, FOXP3þ co-staining
was used to exclude Treg cells from these analyses. Non-
regulatory CD4þ and CD8þ T cells from imiquimod-treated
SCC produced markedly increased levels of IFN-g (Figure 2a
and b). IFN-g was produced by 69% of CD4þ T cells
(SD¼ 3.1, N¼3) and 79% of CD8þ T cells (SD¼7.4, N¼ 3)
from treated tumors, compared with 8.2% of CD4þ
(SD¼ 1.4, N¼3) and 21% of CD8þ T cells (SD¼13,
N¼3) from untreated tumors. Few T cells from either treated
or untreated SCC produced IL-17 (Figure 2a and b). The
percentages of T cells producing granzyme and perforin, two
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Figure 1. Imiquimod treated SCCs are heavily infiltrated by CD8þ T cells that are associated with tumor regression and apoptosis of tumor cells. (a)
Cryosections of SCC treated with imiquimod were stained for CD8þ (green) and Ki-67 (orange) to identify proliferating tumor cells. Treated SCCs had three clear
histological zones: (1) residual tumor, (2) a dense CD8þ T-cell infiltrate, and (3) a deeper fibrotic zone of tumor regression. (b) A higher power view is shown of
the interface between the zones of T-cell infiltration and tumor regression. Residual tumor (arrow) is surrounded by a dense T-cell infiltrate (T) beneath which is a
zone of fibrotic regression (R). (c) An additional imiquimod-treated tumor stained with Hoechst nuclear dye is shown. Residual tumor (arrow) can be identified
by the large atypical keratinocyte nuclei. A zone of dense T-cell infiltrate (T) and an area of fibrotic regression (R) are also evident. (d) CD8þ T cells infiltrates are
associated with tumor cell apoptosis. Hoechst nuclear stain delineates a tumor nodule (arrow) surrounded by T cells (T). TUNEL staining shows widespread
tumor cell apoptosis in areas of dense T-cell infiltrates. Three additional treated tumors showed similar results. Bar¼100 mm.
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molecules associated with T-cell cytotoxicity, were also
increased in imiquimod-treated SCC (Figure 2c–f). Overall
46% of CD4þ T cells from imiquimod-treated SCC produced
granzyme (SD¼11, N¼3) and 43% produced perforin
(SD¼ 5.1, N¼3). Of CD8þ T cells from treated SCC, 81%
produced granzyme (SD¼6.1, N¼ 3) and 73% produced
perforin (SD¼9.4, N¼3).
CD8þ T cells do not proliferate locally within imiquimod-
treated tumors
We have observed a shift in the CD4þ /CD8þ T-cell ratio in
untreated tumors from 1:1 in untreated tumors to 1:10 in
imiquimod-treated tumors, and this shift is associated with a
three-fold increase in the total number of T cells infiltrating
tumors (Clark et al., 2008). Increased numbers of CD8þ T
cells could result from either an influx of T cells from the
blood or from local expansion of tumor-specific T cells
already present within the tumor. To determine whether
CD8þ T cells proliferate locally within imiquimod-treated
SCC, we co-stained cryosections of treated SCC with CD8þ
and the proliferation antigen, Ki-67 (Figure 3). Although
proliferating cells were readily detectable in stained sections,
these
were almost invariably tumor cells. Less than 5% of the
CD8þ T cells present in imiquimod-treated SCC had recently
proliferated, suggesting that the increased number of CD8þ
cells results from enhanced recruitment from the blood
(Figure 3c).
Non-regulatory T cells from imiquimod-treated SCC produce
less IL-10 and TGF-b
We reported earlier that imiquimod treatment is associated
with decreased production of IL-10 and transforming growth
factor-b (TGF-b) by FOXP3þ Treg cells present in SCC (Clark
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Figure 2. Production of IFN-c, perforin, and granzyme is markedly enhanced in T cells from SCC treated with imiquimod. IFN-g is produced by the majority of
both (a) CD4þ and (b) CD8þ T cells in SCC treated with imiquimod, compared with lower production in untreated tumors. IL-17 production was low in both
treated and untreated tumors. (c) CD4þ and CD8þ T cells from SCC had increased co-expression of perforin and granzyme after imiquimod therapy. Study of
additional treated tumors confirmed enhanced production of perforin and granzyme by both (e) CD4þ and (f) CD8þ T cells.
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et al., 2008). We studied the production of IL-10 and TGF-b
by non-regulatory T cells and found that in untreated SCC,
significant amounts of IL-10 were produced by both FOXP3þ
regulatory and FOXP3 non-regulatory T cells (Figure 4a).
Non-regulatory T cells from tumors treated with imiquimod
produced less IL-10 (Figure 4b–d, mean 43%, SD¼ 2.1, N¼ 3
from untreated tumors compared with mean 20%, SD¼ 4.1,
N¼3 from treated tumors). TGF-b was also produced by a
mean 12% of non-regulatory T cells in untreated SCC and
production was decreased to 2% in imiquimod-treated
tumors (Figure 4e, SD¼ 1.5, N¼ 3 from untreated tumors
and SD¼1.1, N¼ 3 from treated tumors). These results
indicate that non-regulatory T cells are also a significant
source of immunosuppressive cytokines in SCC and that
production of these cytokines is decreased by treatment with
imiquimod.
IL-10 has been reported to be produced by SCC tumor
cells (Kim et al., 1995). We immunostained cryosections of
SCC and did observe detectable IL-10 production by tumor
cells (Figure 5a). Also, intracellular cytokine analysis of
the SCC cell line, SCC13, demonstrated IL-10 production
(Figure 5b).
Treatment of normal human skin with imiquimod enhances
T-cell activation, and reduces IL-10 production but does not
affect the production of IFN-c
Imiquimod could alter the biology of T cells in SCC by
recruiting different T-cell populations into the tumor, by
altering the activity or function of T cells within the tumor, or
by a combination of these two mechanisms. To separate the
differential effects of recruitment versus local T-cell modula-
tion, we studied the effects of imiquimod on the population of
T cells resident in normal human skin. In order to focus on
non-regulatory T cells, FOXP3þ Treg cells were excluded
from all analyses.
For these studies, imiquimod was added to cultures of
normal skin for 1 week before T-cell isolation (Clark et al.,
2006). T cells from the imiquimod-treated skin had increased
expression of the early activation antigen CD69 but
decreased levels of CD25 expression (Figure 6a). We found
that a large population of T cells from normal human skin
produced IL-10 (Figure 6b). Imiquimod treatment of normal
skin T cells reduced the production of IL-10 but had no effect
on the production of IFN-g and IL-17 (Figure 6c and d). In
contrast to a prior report that in vitro treatment with
imiquimod induced perforin production in human CD8þ T
cells (Ambach et al., 2004), we observed no change in
perforin and granzyme production in CD3þ T cells after
imiquimod treatment (data not shown). TGF-b was produced
at baseline byo2% of skin-resident effector T cells; we were
therefore unable to study the reduction of TGF-b production
after treatment with imiquimod. The addition of imiquimod
to purified skin T cells removed first from the skin
microenvironment had no effect on the expression of
activation antigens or on cytokine production, confirming
earlier work that showed that the effect of imiquimod on
T cells is indirect and requires the presence of other,
imiquimod-responsive cell types (Wagner et al., 1999).
DISCUSSION
The increased incidence of SCC in patients on T-cell-
immunosuppressive medications suggests that T cells have
a critical function in controlling these tumors. T cells are
present within SCC but do not control tumor growth. We
found earlier that SCCs exclude CLAþ skin homing T cells
and instead recruit FOXP3þ Treg cells (Clark et al., 2008).
Thus, tumors persist, in part, because of aberrant T-cell
homing.
Imiquimod is a topical immune response modifier that is
effective in the treatment of basal cell carcinomas, SCCs, and
AKs (Hurwitz et al., 2003; Schon et al., 2003; Patel et al.,
2006; Peris et al., 2006). Imiquimod induces tumor regression
through both immunological and non-immunological me-
chanisms by serving as a TLR7 agonist and by binding to
adenosine receptors (Hemmi et al., 2002; Jurk et al., 2002;
Lee et al., 2003; Schon et al., 2003; Gorden et al., 2005).
Cells of the innate immune system are clearly critical to
the initiation of immune reactions in response to TLR agonists
such as imiquimod. Clinical response to topical imiquimod
therapy has been associated with the migration of plasmacy-
toid dendritic cells into the skin and subsequent cytokine
production (Palamara et al., 2004; Urosevic et al., 2005). We
have found that the effects of imiquimod on endothelial and
T cells are all indirect and require the presence of other,
imiquimod-responsive cell types (Clark et al., 2008).
Despite the importance of innate cells in the first stages
of TLR7 agonist responses, tumor destruction and the
subsequent formation of immune memory are ultimately
SCC17SCC13SCC8SCC17SCC13SCC8
0
10
20
30
40
50
60
70
80
90
100
%
 K
i6
7–
 
CD
8 
T 
ce
lls
%
 K
i6
7+
 
CD
8 
T 
ce
lls
Non-proliferativeProliferative
0.0
2.5
5.0
7.5
10.0
12.5
15.0
a
c
b
Figure 3. CD8þ T cells do not proliferate locally within imiquimod-treated
tumors. (a) Co-staining of cryosections of imiquimod-treated SCC with
CD8þ (green) and Ki-67 (orange) showed proliferation of tumor cells but few
CD8þ T cells. (b) Higher power view of a second tumor with similar findings.
(c) Quantification of CD8þ T-cell proliferation in three treated tumors.
Bar¼100 mm.
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T-cell-mediated events. It is therefore critical to understand
the downstream effects of TLR agonists such as imiquimod on
the activity and effector functions of T cells.
Imiquimod therapy induced marked shifts in the T-cell
populations infiltrating SCC. Untreated SCCs are populated
by non-cutaneous central memory T cells, a cell type not
usually found in the skin (Clark et al., 2008). These T cells are
unlikely to be tumor-specific and are aberrantly recruited into
the tumor by unknown mechanisms. Topical therapy with
imiquimod induced a massive recruitment of CLAþ skin-
homing CD8þ effector T cells into SCC. Observation of
multiple tumors at various stages of immune destruction
allowed us to observe that these T cells formed a dense,
band-like infiltrate that originated in the deep dermis and
migrated up, inducing tumor cell death at the leading edge
and leaving behind areas of fibrotic tumor regression
(Figure 1). We found little proliferation of CD8þ T cells in
SCC, suggesting that the increased number of these cells is a
result of enhanced recruitment from the blood (Figure 3). This
result also suggests that proliferation of tumor-specific T cells
may occur instead in the draining lymph nodes. Immature
dendritic cells are numerous in untreated SCCs, but
imiquimod induces dendritic cell maturation and likely
stimulates migration to the lymph nodes (Clark et al.,
2008). Imiquimod therapy may therefore enhance antigen
presentation and proliferation of tumor-specific T cells in the
draining lymph nodes.
T cells from imiquimod-treated tumors produced large
amounts of IFN-g, a Th1 cytokine critical for antitumor
immune responses (Nakajima et al., 2001). T cells from
imiquimod-treated tumors also showed enhanced production
of perforin and granzyme, two proteins that mediate killing
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Figure 4. Effector T cells from imiquimod-treated SCC produce less IL-10 and TGF-b. (a) Non-regulatory T cells in untreated SCC are a significant source
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by cytotoxic T cells. Our results in SCC agree with prior gene
profiling studies in basal cell carcinomas showing a marked
upregulation of genes associated with cytotoxic T-cell
function after an initial phase of innate cell activation (Panelli
et al., 2007).
In addition to these pro-inflammatory T-cell changes, non-
regulatory T cells from imiquimod-treated SCC also had
reduced production of the immunosuppressive cytokines,
IL-10 and TGF-b (Figure 4). Non-regulatory T cells were a
significant source of IL-10 and TGF-b in untreated SCC, and
this production was significantly decreased in imiquimod-
treated tumors. Untreated SCC containB50% Treg cells and
half of these Treg cells produce IL-10 (Clark et al., 2008).
Approximately 45% of non-regulatory T cells in SCC also
produce IL-10, suggesting that nearly half of the T cells in
untreated SCC produce IL-10 and that contributions from
Treg cells and non-regulatory T cells are roughly equivalent.
The tumor cells of SCC have also been reported to produce
IL-10 (Kim et al., 1995). We observed IL-10 production by
tumor cells as shown by immunostaining of SCC tumors and
intracellular cytokine analysis of the cell line SCC13
(Figure 5). Thus, IL-10 is produced by at least three cell types
Control Anti-IL-10
61105
104
103
102
39
PE
IL-10 APC
–650 0 10
3 104 105
Figure 5. Human SCC tumor cells also produce IL-10. (a) Immunostaining of untreated SCC shows that tumor cells, identified by their large, atypical nuclei
on Hoechst stain (lower panels, blue), synthesize IL-10. The left panel (control) shows staining with secondary and tertiary antibodies alone and the right panel
also includes the primary anti-IL-10 antibody. (b) The SCC cell line, SCC13, produces IL-10. SCC13 tumor cell lines were analyzed for IL-10 production by
intracellular cytokine analysis. Bar¼ 100mm.
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in human SCC: tumor-infiltrating lymphocytes (both regula-
tory and non-regulatory T cells) and the tumor cells
themselves.
Imiquimod has marked effects on T-cell recruitment into
tumors, but it may also locally affect the phenotype and
function of T cells within the tumor. To separate out the
differential effects of recruitment versus local T-cell modula-
tion, we studied the effects of imiquimod on T cells isolated
from normal skin samples treated in vitro with imiquimod.
Imiquimod enhanced T-cell activation as evidenced by
increased expression of CD69 (Figure 6a). We found that
over 25% of FOXP3 CD4þ T cells from normal human skin
expressed IL-10 (Figure 6b and c). This population of IL-10-
producing T cells has not been observed earlier and may play
a role in dampening immune responses in normal skin.
Imiquimod treatment significantly decreased IL-10 produc-
tion by both CD4þ and CD8þ T cells, but had no effect on
the production of IFN-g or IL-17 (Figure 6c and d). Imiquimod
may therefore alter the inflammatory tone in normal skin by
inhibiting the tonic production of anti-inflammatory cyto-
kines such as IL-10. The lack of effect on IFN-g production
suggests that the differences we observe in tumors treated
in vivo reflect the recruitment of Th1-biased T cells into the
tumor.
On the basis of our observations, we have separated the
effects of imiquimod on tumor-infiltrating T cells into those
reflecting differential migration versus local modulation of
T-cell activity (Figure 7). In this model, activation of the
tumor endothelium plays a critical role in the recruitment of
skin-homing CLAþ T cells, which contain the subset of T
cells specific for SCC (Clark et al., 2008). These T cells
produce IFN-g, granzyme, and perforin, leading to tumor cell
destruction. Prior to imiquimod therapy,B50% of the T cells
infiltrating SCC are FOXP3þ Treg cells (Clark et al., 2008).
Treg cells can suppress the activation, cytokine production,
and cytotoxic activity of other T cells, and their presence has
the potential to inhibit local immune response to the tumor
(Sakaguchi et al., 1995; Hori et al., 2003). Imiquimod-
mediated activation of the endothelium leads to an influx
of CD8þ T cells, diluting the percentage of
tumor Treg cells to levels found in normal skin. In addition
to this recruitment-mediated effect, imiquimod also
inhibits the ability of Treg cells to suppress T-cell responses.
Imiquimod-treated Treg cells produce less IL-10 and
TGF-b, and have lower levels of expression of molecules
critical for suppressive function, including FOXP3þ ,
CD39, and CD73 (Clark et al., 2008). Imiquimod also acts
locally to induce IL-6 production by non-regulatory T cells,
likely rendering them resistant to suppression (Kono et al.,
1994; Gibson et al., 1995, 2002; Pasare and Medzhitov,
2003; Korn et al., 2007). We report here that imiquimod has
additional effects on non-regulatory T cells, inducing
their activation and inhibiting tonic expression of IL-10.
Imiquimod therefore acts locally on both Treg cells and
non-regulatory T cells to block tolerogenic signals within
the tumor.
Imiquimod can induce the immunological destruction of
basal cell carcinomas, AKs, and Bowen’s disease (Gupta
et al., 2005; Schulze et al., 2005; Patel et al., 2006). In
addition to treating existing AKs, imiquimod decreased the
number of new and recurrent lesions in the year following
therapy, suggesting a prolonged enhancement of immunolo-
gical memory (Krawtchenko et al., 2007). Imiquimod is
increasingly being reported as an effective therapy for
invasive SCC in normal or in immunosuppressed patients
who are poor surgical candidates (Nouri et al., 2003; Hengge
and Schaller, 2004; Martin-Garcia, 2005; Palungwachira
et al., 2005; Konstantopoulou et al., 2006; Peris et al., 2006).
Our studies support the use of imiquimod as an adjunctive
therapy to reduce tumor size before Mohs’ surgery, to treat
residual disease after surgery, or as a monotherapy for
unresectable tumors.
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Figure 7. The effects of imiquimod on tumor-associated T cells: consequences on T-cell recruitment versus local modulation of T-cell function. A summary of
the current studies and our prior work (Clark et al., 2008) is shown. (a) Untreated SCCs lack vascular expression of E-selectin and are populated by non-
cutaneous central memory T cells, 50% of which are FOXP3þ Treg cells. (b) Imiquimod treatment of SCC induces vascular E-selectin and the recruitment
of tumor-specific CLAþ skin-homing T cells. These cells dilute out Treg cells resident in the tumor and their activation within the tumor leads to production
of IFN-g, perforin, granzyme, and to tumor cell destruction. (c) Imiquimod also acts locally on tumor T cells, indirectly inducing the production of IL-6 by
non-regulatory effector T cells (Teff), likely rendering them resistant to suppression. Imiquimod also reduces Teff production of IL-10 and TGF-b, thereby
reducing tonic inhibitory signals within the tumor. Imiquimod also acts on to regulatory T cells (Treg cells) to reduce their ability to suppress through cytokine
production (IL-10, TGF-b) and contact suppression (CD39, CD73).
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Squamous cell carcinomas evade immune responses, at
least in part, by excluding skin-homing effector T cells and
by recruiting Treg cells (Clark et al., 2008). Imiquimod
neutralizes both of these defenses, restoring appropriate
T-cell homing and reducing the percentage and suppressive
ability of Treg cells. Reduced vascular addressin expression
and impaired T-cell homing has been described in human
melanoma, breast, gastric and lung cancers (Piali et al., 1995;
Madhavan et al., 2002; Weishaupt et al., 2007). Treg cells
inhibit immune responses to a large number of human
cancers, including melanoma, lung, breast, ovarian and renal
cell cancers (Zou, 2006). Imiquimod’s efficacy in the
treatment of SCC suggests that TLR7 agonists may have a
role in the treatment of other malignancies that use similar
mechanisms of immune evasion.
Although two short-term trials have found that imiquimod
is safe and effective in the prevention of SCC in transplant
recipients, the long-term effects of imiquimod on organ
tolerance are unknown (Brown et al., 2005; Ulrich et al.,
2007). Concerns about inducing widespread immune activa-
tion and graft rejection continue to limit the use of this
medication in the treatment of transplant recipients in whom
SCCs are a major cause of morbidity and mortality. The
effects of imiquimod on vascular addressin expression and
T-cell function are indirect (Wagner et al., 1999; Clark et al.,
2008). Once the cytokines or other molecules that mediate
imiquimod’s effects have been identified, these agents could
be incorporated into delayed release delivery systems and
administered directly to tumors. Local release of these agents
within the tumor microenvironment could induce immuno-
logical destruction of tumors without the risk of widespread
immune activation engendered by TLR agonists such as
imiquimod. These agents would also obviate the requirement
for TLR7 responder cells, such as plasmacytoid dendritic
cells, to be present within tumors. A lack of plasmacytoid
dendritic cells in tumors correlated with the lack of response
to imiquimod in human basal cell carcinoma (Urosevic et al.,
2005).
The skin is an accessible site in which human tumor
immunity can be analyzed because immune reactions in the
skin are visible, easily sampled, and can be manipulated with
topical medications. By studying SCC, we can observe,
sample, and modify the human immune response to cancer.
Insights gained from these studies will likely be applicable to
the treatment of both cutaneous and non-cutaneous malig-
nancies.
MATERIALS AND METHODS
SCC samples
Tumor samples consisted of curetted tumor removed before excision
of the first Mohs’ section during Mohs’ micrographic excision of
biopsy-proven SSCs. Acquisition of tumor samples and all studies
were approved by the Institutional Review Board (IRB) of the
Partners Human Research Committee and were performed in
accordance with the Declaration of Helsinki Principles. Patient
consent was not required because the IRB determined that collection
of discarded SCC tumors did not meet the definition of human
subjects research. Tumors were divided into bread loaf sections.
Adjacent sections were used for (a) immunofluorescence studies to
confirm the presence of invasive tumor cells and (b) T-cell isolation,
as described below. Imiquimod-treated tumors were obtained from
patients treated daily with topical imiquimod for 10–14 days before
excision.
Immunofluorescence studies
Freshly excised SCC tumors were embedded in OCT (optimal cutting
temperature), frozen, and stored at 80 1C until use. Cryosections of
5mm were cut, air-dried, fixed for 5minutes in acetone, rehydrated
in phosphate-buffered saline, and blocked with 20mgml1 of human
IgG (Jackson, Bar Harbor, ME) for 15minutes at room temperature.
The sections were incubated with a primary antibody for 30minutes,
then rinsed three times in phosphate-buffered saline/1% BSA for
5minutes. The sections were stained with 0.5 mgml1 Hoechst stain
for 2minutes, rinsed briefly in phosphate-buffered saline/1% BSA,
mounted using Prolong anti-fade mounting medium (Invitrogen,
Carlsbad, CA), and examined immediately by immunofluorescence
microscopy. Antibodies were obtained from BD (Becton Dickinson,
Franklin Lakes, NJ), (CD8þ FITC, 1:20 dilution; Ki-67 PE, 1:5
dilution). IL-10 staining: rat anti-human IL-10 (BD, 1:5 dilution),
secondary FITC goat anti-rat IgG (Invitrogen, 1:50), and tertiary
rabbit polyclonal anti-FITC conjugated to Alexa Fluor 488 (Mole-
cular Probes, Eugene, OR, 1:50). In all studies, Hoechst nuclear stain
was used to confirm the presence of invasive tumor. TUNEL staining
was performed on sections from untreated and treated SCC using the
ApopTag Red In situ Apoptosis Detection Kit (Chemicon, Billarica,
MA) according to the manufacturer’s instructions. Following the final
wash step, the sections were stained with Hoechst dye and mounted
as described above. The sections were photographed using a Nikon
Eclipse 6600 microscope (Nikon, Melville, NY) equipped with a
Nikon  40/0.75 Plan Fluor objective lens. Images were captured
with a SPOT RT model 2.3.1 camera (Diagnostic Instruments,
Sterling Heights, MI) and were obtained using SPOT 4.0.9 software
(Diagnostic Instruments).
Isolation of T cells from SCC tumors and normal skin
The clinically evident portions of biopsy-proven invasive SCC
tumors were obtained. The tumors were divided into bread loaf
sections. One section was histologically examined to confirm the
presence or absence of invasive SCC tumor. Sections without
evidence of tumor were designated peritumoral. Tumor-infiltrating
T cells were isolated from sections adjacent to those studied by
histology. T cells were isolated from SCC tumors in the absence of
exogenous cytokines as described previously (Clark et al., 2006). For
normal skin studies, T cells from the skin discarded after plastic
surgery procedures were isolated from 3-week explant cultures
maintained in the presence of 100Uml1 IL-2 (R&D Systems,
Minneapolis, MN) and 20 ngml1 of IL-15 (R&D Systems) as
described previously (Clark et al., 2006).
Flow cytometry studies
Flow cytometry analysis of T cells was carried out using directly
conjugated monoclonal antibodies purchased from BD Biosciences
(CD3þ , CD4þ , CD8þ , CD25, and CD69) and eBioscience (San
Diego, CA) (FOXP3þ , clone PCH101). Staining for FOXP3þ and
activated NF-kB p65 was performed as per the manufacturer’s
instructions. Analysis of flow cytometry samples was carried out on
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Becton Dickinson FACScan or FACSCanto instrument, and data were
analyzed using FACSDiva software (V5.1).
Analyses of cytokine, granzyme, and perforin production
T cells were stimulated with 50 ngml1 PMA (phorbol 12-myristate
13-acetate; Sigma, St Louis, MO) and 750 ngml1 ionomycin
(Invitrogen) for 6 hours, with the inclusion of 10mgml1 brefeldin-
A (Calbiochem) for the last 5 hours of incubation. SCC13 tumor cells
(kindly provided by Dr James Rheinwald) were cultured and
brefeldin-A was added to the cultures 12 hours before analysis.
The cells were stained for surface marker expression, fixed,
permeabilized, and stained with anti-cytokine, granzyme, or
perforin antibodies (IL-17, IL-10, IFN-g, TGF-b, granzyme, and
perforin, all from BD Pharmingen, Franklin Lakes, NJ), and examined
by flow cytometry. We observed loss of cytokine staining in
unstimulated samples lacking PMA and ionomycin (but treated with
brefeldin-A) and in samples treated with PMA and ionomycin but
lacking brefeldin-A, suggesting that T-cell stimulation was required
for cytokine production and that cytokines synthesized by T cells
were secreted.
Imiquimod treatment of normal skin T cells
Imiquimod stocks of 10,000 (30mM) were prepared by solubiliz-
ing imiquimod cream in DMSO. The stocks were then diluted 1:10
in culture medium and 1ml of this 1,000 stock was added to each
microliter of culture medium (end concentration was 3mM). For
control medium samples, an equivalent amount of DMSO was
added to the control culture medium (a 1:10,000 dilution). Normal
skin explant cultures were set up and maintained in 100Uml1 of
IL-2 (R&D Systems) and 20 ngml1 IL-15 (R&D Systems) to produce
an expanded population of skin-resident T cells as described
previously (Clark et al., 2006). Imiquimod or control DMSO was
added to 2-week skin explant cultures and replenished with feeds for
1 week; cells were harvested on week 3. In separate experiments,
T cells were harvested from the 2-week skin explant cultures (grown
in IL-2 and IL-15 for 2 weeks) and thereafter cultured separately with
IL-2 and IL-15 and with or without imiquimod for 1 week.
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